Gamble Jones Investment Counsel increased its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 4.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,287 shares of the medical research company’s stock after purchasing an additional 1,789 shares during the period. Gamble Jones Investment Counsel’s holdings in Amgen were worth $7,977,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in shares of Amgen by 3.4% in the second quarter. BlackRock Inc. now owns 47,717,316 shares of the medical research company’s stock valued at $8,793,346,000 after buying an additional 1,585,911 shares in the last quarter. Morgan Stanley increased its holdings in shares of Amgen by 0.5% in the second quarter. Morgan Stanley now owns 6,753,145 shares of the medical research company’s stock valued at $1,244,470,000 after buying an additional 34,674 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Amgen by 1,334.9% in the second quarter. Nuveen Asset Management LLC now owns 4,942,807 shares of the medical research company’s stock valued at $910,860,000 after buying an additional 4,598,329 shares in the last quarter. Nordea Investment Management AB increased its holdings in shares of Amgen by 5.0% in the first quarter. Nordea Investment Management AB now owns 4,709,467 shares of the medical research company’s stock valued at $894,700,000 after buying an additional 225,485 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Amgen by 9.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 2,780,461 shares of the medical research company’s stock valued at $512,383,000 after buying an additional 239,576 shares in the last quarter. 76.24% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ AMGN traded down $0.96 on Monday, hitting $193.98. 740,856 shares of the stock were exchanged, compared to its average volume of 2,597,543. Amgen, Inc. has a 52-week low of $166.30 and a 52-week high of $211.90. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The company has a market capitalization of $117.17 billion, a price-to-earnings ratio of 13.47, a P/E/G ratio of 2.54 and a beta of 1.11. The company’s 50-day moving average price is $200.83 and its two-hundred day moving average price is $185.78.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the company posted $3.83 EPS. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. Equities analysts predict that Amgen, Inc. will post 14.3 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 6th. Stockholders of record on Thursday, August 15th were issued a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a dividend yield of 2.99%. The ex-dividend date was Wednesday, August 14th. Amgen’s dividend payout ratio is currently 40.28%.
In other news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $206.70, for a total transaction of $413,400.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at approximately $3,376,651.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director R Sanders Williams sold 425 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the transaction, the director now owns 16,336 shares in the company, valued at $2,990,141.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,851 shares of company stock worth $3,659,900. 0.25% of the stock is currently owned by corporate insiders.
AMGN has been the topic of several research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $230.00 price target (up previously from $221.00) on shares of Amgen in a report on Thursday, September 5th. William Blair reaffirmed a “hold” rating on shares of Amgen in a report on Friday, August 30th. JPMorgan Chase & Co. set a $198.00 price target on Amgen and gave the company a “hold” rating in a report on Friday, September 6th. Citigroup reaffirmed a “buy” rating on shares of Amgen in a report on Monday, August 12th. Finally, Leerink Swann reiterated a “hold” rating on shares of Amgen in a research report on Thursday, September 12th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $217.33.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Article: Price Target
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.